

3rd ANNUAL KIDNEY CONGRESS & 16th International Conference on **NEPHROLOGY & THERAPEUTICS** October 19-20, 2018 | New York, USA

Comparative study on the economic assessment of hemodialysis and peritoneal dialysis units in the region and urban centers of Greece with units from the rest of the European Union and beyond

Marilena G Koukou¹, Vassilios E Smyrniotis², Nikolaos F Arkadopoulos², Eirini I Grapsa³

¹University of Athens, Greece

²Attikon University Hospital, Greece

³Aretaieio Hospital, Greece

We made an assessment of the cost of Hemodialysis (HD) in the period of economic crisis compared to international data through the recording of demographic characteristics and the total cost of treatment of a sample of 2,586 subjects undergoing HD (27% of patients in HD). The total cost in Greece includes the procedure, consumables, medications, laboratory or non-examinations, food allowance, and transportation costs. The mean age was determined at 68.7±14.1 years (63.7% men) and 66.3±13.2 years (49.4% men) for the Czech Republic up to 68.9±15 years (58, 8% men) for France. In Greece, the most common cause of end-stage renal disease for patients undergoing HD is the "unknown cause" with 33.02%. Similar is the situation in Spain (30.3%), Italy (30.3%), Hungary (41.7%), Poland (25.8%) and Portugal (28.1%). The average annual cost of HD per patient based on units data from Belgium, Germany, the Netherlands, England, and France was estimated to be € 66,212, € 44,575, € 65,739, € 29,322 and € 53,758 respectively; Greece was estimated at € 39,800 for public hospitals. At this point, it should be noted that in Belgium and Germany, there is a limit on the number of examinations that can be performed per month, whereas in any of the previous countries (excluding Greece) you do not include the annual cost of the medicines granted by the mouth, with the exception of the US, where drugs are included in dialysis costs starting in 2014. The population of patients with dialysis in our country has common characteristics with the patients of other countries in terms of age and gender, but the cost of treatment seems to be much lower, than the other countries.

Biography

She has completed her PhD at the age of 34 years from National and Kapodistrian University of Athens in Medicine. She worked like Medical Science Liaison & Tender Manager. She is acting as bridge (MSL) between the company and members of the healthcare industry, finding efficient ways to manage collaboration with the physicians, as well as to improve interaction with KOLs. Working throughout a product's lifecycle as local regulatory representative, helping to ensure that is utilized effectively and planning, implementation & development of integrated proposals-solutions for both public and private sectors. She is handling the communication with company suppliers abroad (from all major manufacturing countries such as Switzerland, England, Nederland, Germany, Italy, Austria etc). She is managing procedures for respective ISO Certification 9001:2008, recycling system and EKAPTY (formerly EKEVYL). I am also representing the company at opening of the tenders in both Public and Private Hospitals.

marilenakoukou@gmail.com

Notes: